No absolute bioavailability data were provided. However, the results of the mass balance study indicate that the bioavailability might be 60%, provided that no degradation of the parent compound occurs in the faeces. However, metabolites M13, M10, M7 and M1 have been detected in plasma. M12 is formed by oxidation of M13 and M4 is formed by oxidation of M9, the product of demethylation of the PEG chain shown to be produced by CYP3A in vitro. In addition, the applicant further provided information that all identified metabolites are not formed by reductive processes, as such limiting the probability that these have been formed due to degradation of naloxegol in the faeces. Only for the remaining unidentified component (MX1) this is not clear; however, as this component represents only 2.2% of dose, it is considered unlikely that this would change the conclusions significantly.